{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:35:02Z","timestamp":1773434102497,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.amjcard.2024.02.033","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T10:10:15Z","timestamp":1709287815000},"page":"63-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Safety and Efficacy of Enoxaparin During Low-Risk Elective Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0438-6409","authenticated-orcid":false,"given":"Hani","family":"Alturkmani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Uretsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swetal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu'nes","family":"Albadaineh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Alqaisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malek","family":"Alaiwah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danish","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Rollefson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2024.02.033_bib0001","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1160\/TH08-01-0032","article-title":"Heparin and low-molecular-weight heparin","volume":"99","author":"Gray","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-642-23056-1_3","article-title":"The anticoagulant and antithrombotic mechanisms of heparin","volume":"207","author":"Gray","year":"2012","journal-title":"Handb Exp Pharmacol"},{"issue":"suppl","key":"10.1016\/j.amjcard.2024.02.033_bib0003","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0004","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ccd.20352","article-title":"Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis","volume":"65","author":"Borentain","year":"2005","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0006","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2009.08.077","article-title":"Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test","volume":"55","author":"Silvain","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0007","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jcin.2009.11.012","article-title":"Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated intervention with enhanced reperfusion speed to stop events)","volume":"3","author":"Montalescot","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0008","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0009","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/j.1538-7836.2011.04445.x","article-title":"Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis","volume":"9","author":"Navarese","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0010","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention","volume":"355","author":"Montalescot","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0011","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ccd.22674","article-title":"Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention","volume":"77","author":"Brieger","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0012","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/j.jacc.2010.02.005","article-title":"NCDR Registry Participants. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry","volume":"55","author":"Peterson","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003070","article-title":"Temporal trends in the risk profile of patients undergoing outpatient percutaneous coronary intervention: a report from the national cardiovascular data registry's CathPCI registry","volume":"9","author":"Vora","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0014","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jcin.2020.10.015","article-title":"Elective percutaneous coronary intervention in ambulatory surgery centers","volume":"14","author":"Li","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ahj.2008.08.023","article-title":"Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials","volume":"157","author":"Jolly","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0016","first-page":"e23973","article-title":"Factors impacting stent thrombosis in patients with percutaneous coronary intervention and coronary stenting: a systematic review and meta-analysis","volume":"14","author":"Nso","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0017","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.jacc.2018.09.013","article-title":"Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: the ultimate trial","volume":"72","author":"Zhang","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0018","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","article-title":"Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice","volume":"42","author":"Fareed","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0019","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(02)02531-7","article-title":"A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention","volume":"40","author":"Choussat","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ccd.10305","article-title":"Pharmacokinetics of intravenous\/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions","volume":"57","author":"Aslam","year":"2002","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0021","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.amjcard.2005.01.071","article-title":"Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (The action trial)","volume":"95","author":"Madan","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0022","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.292.1.55","article-title":"\u2018A to Z\u2019 Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial","volume":"292","author":"Blazing","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2024.02.033_bib0023","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:12:23Z","timestamp":1731071543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914924001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":23,"alternative-id":["S0002914924001577"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.02.033","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Enoxaparin During Low-Risk Elective Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}